|
1
|
Chudnovsky Y, Khavari PA and Adams AE:
Melanoma genetics and the development of rational therapeutics. J
Clin Invest. 115:813–824. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Devesa SS, Fears TR and Hartge P:
Cancer surveillance series: changing patterns of cutaneous
malignant melanoma mortality rates among whites in the United
States. J Natl Cancer Inst. 92:811–818. 2000. View Article : Google Scholar
|
|
3
|
Jemal A, Devesa SS, Hartge P and Tucker
MA: Recent trends in cutaneous melanoma incidence among whites in
the United States. J Natl Cancer Inst. 93:678–683. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
6
|
Flaherty KT, Puzanov I, Kim KB, et al:
Inhibition of mutated, activated BRAF in metastatic melanoma. N
Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nashan D, Muller ML, Grabbe S, Wustlich S
and Enk A: Systemic therapy of disseminated malignant melanoma: an
evidence-based overview of the state-of-the-art in daily routine. J
Eur Acad Dermatol Venereol. 21:1305–1318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrovski G, Gurusamy N and Das DK:
Resveratrol in cardiovascular health and disease. Ann NY Acad Sci.
1215:22–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szkudelska K and Szkudelski T:
Resveratrol, obesity and diabetes. Eur J Pharmacol. 635:1–8. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Signorelli P and Ghidoni R: Resveratrol as
an anticancer nutrient: molecular basis, open questions and
promises. J Nutr Biochem. 16:449–466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: preclinical and clinical studies.
Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
|
|
12
|
Niles RM, McFarland M, Weimer MB, Redkar
A, Fu YM and Meadows GG: Resveratrol is a potent inducer of
apoptosis in human melanoma cells. Cancer Lett. 190:157–163. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fulda S and Debatin KM: Sensitization for
anticancer drug-induced apoptosis by the chemopreventive agent
resveratrol. Oncogene. 23:6702–6711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ivanov VN, Partridge MA, Johnson GE, Huang
SX, Zhou H and Hei TK: Resveratrol sensitizes melanomas to TRAIL
through modulation of antiapoptotic gene expression. Exp Cell Res.
314:1163–1176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fulda S and Debatin KM: Sensitization for
tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis by the chemopreventive agent resveratrol. Cancer Res.
64:337–346. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang Y, Bradley MJ, Cook KM, Herrick EJ
and Nicholl MB: A potential role for resveratrol as a radiation
sensitizer for melanoma treatment. J Surg Res. 183:645–653. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim MY: Nitric oxide triggers apoptosis in
A375 human melanoma cells treated with capsaicin and resveratrol.
Mol Med Rep. 5:585–591. 2012.PubMed/NCBI
|
|
18
|
Osmond GW, Augustine CK, Zipfel PA,
Padussis J and Tyler DS: Enhancing melanoma treatment with
resveratrol. J Surg Res. 172:109–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tak JK, Lee JH and Park JW: Resveratrol
and piperine enhance radiosensitivity of tumor cells. BMB Rep.
45:242–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakurai H, Suzuki S, Kawasaki N, et al:
Tumor necrosis factor-alpha-induced IKK phosphorylation of
NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5,
and TAK1 signaling pathway. J Biol Chem. 278:36916–36923. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haq R, Yokoyama S, Hawryluk EB, et al:
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that
confers resistance to BRAF inhibition. Proc Natl Acad Sci USA.
110:4321–4326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trapp V, Parmakhtiar B, Papazian V,
Willmott L and Fruehauf JP: Anti-angiogenic effects of resveratrol
mediated by decreased VEGF and increased TSP1 expression in
melanoma-endothelial cell co-culture. Angiogenesis. 13:305–315.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Chiu J, Zhang H, et al:
Autophagic cell death induced by resveratrol depends on the
Ca(2+)/AMPK/mTOR pathway in A549 cells. Biochem Pharmacol.
86:317–328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang H, Shang X, Wu H, et al: Resveratrol
downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma
cells. J Exp Ther Oncol. 8:25–33. 2009.PubMed/NCBI
|
|
26
|
Vaira V, Lee CW, Goel HL, Bosari S,
Languino LR and Altieri DC: Regulation of survivin expression by
IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao W, Bao P, Qi H and You H: Resveratrol
down-regulates survivin and induces apoptosis in human
multidrug-resistant SPC-A-1/CDDP cells. Oncol Rep. 23:279–286.
2010.PubMed/NCBI
|
|
28
|
Hayashibara T, Yamada Y, Nakayama S, et
al: Resveratrol induces downregulation in survivin expression and
apoptosis in HTLV-1-infected cell lines: a prospective agent for
adult T cell leukemia chemotherapy. Nutr Cancer. 44:193–201. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shankar S, Siddiqui I and Srivastava RK:
Molecular mechanisms of resveratrol
(3,4,5-trihydroxy-trans-stilbene) and its interaction with
TNF-related apoptosis inducing ligand (TRAIL) in
androgen-insensitive prostate cancer cells. Mol Cell Biochem.
304:273–285. 2007. View Article : Google Scholar
|
|
30
|
Singh SK, Moretta D, Almaguel F, Wall NR,
De Leon M and De Leon D: Differential effect of proIGF-II and
IGF-II on resveratrol induced cell death by regulating survivin
cellular localization and mitochondrial depolarization in breast
cancer cells. Growth Factors. 25:363–372. 2007. View Article : Google Scholar
|
|
31
|
Singh RP, Tyagi A, Sharma G, Mohan S and
Agarwal R: Oral silibinin inhibits in vivo human bladder tumor
xenograft growth involving down-regulation of survivin. Clin Cancer
Res. 14:300–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Talantov D, Mazumder A, Yu JX, et al:
Novel genes associated with malignant melanoma but not benign
melanocytic lesions. Clin Cancer Res. 11:7234–7242. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Velculescu VE, Madden SL, Zhang L, et al:
Analysis of human transcriptomes. Nat Genet. 23:387–388. 1999.
View Article : Google Scholar
|
|
34
|
Adhami VM, Afaq F and Ahmad N: Suppression
of ultraviolet B exposure-mediated activation of NF-kappaB in
normal human keratinocytes by resveratrol. Neoplasia. 5:74–82.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Widlund HR, Horstmann MA, Price ER, et al:
Beta-catenin-induced melanoma growth requires the downstream target
Microphthalmia-associated transcription factor. J Cell Biol.
158:1079–1087. 2002. View Article : Google Scholar
|
